<DOC>
	<DOCNO>NCT00663767</DOCNO>
	<brief_summary>This Phase 2 study design test ability investigational study drug ARRY-371797 reduce pain postoperative pain model ( third molar extraction ) , evaluate drug 's safety . Approximately 250 subject US enrol study .</brief_summary>
	<brief_title>A Study ARRY-371797 Subjects Undergoing Third Molar Extraction</brief_title>
	<detailed_description />
	<mesh_term>Toothache</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Key Scheduled outpatient oral surgical procedure remove 3 third molar , least 1 mandibular fully partially impacted bone . Females childbearing potential must willing use acceptable method contraception within 14 day prior first dose study drug completion followup procedure . Body weight &gt; 50 kg ( 110 lb ) . Good health determine medical history , physical examination , vital sign clinical laboratory result nonclinical significance . Additional criterion exist . Key Evidence history clinically significant dermatologic , hematological , renal , endocrine ( e.g . poorly control diabetes ) , pulmonary , gastrointestinal , cardiovascular , hepatic , neurologic , ophthalmologic , allergic disease ( include clinically significant drug allergy could impact conduct study , exclude untreated , asymptomatic , seasonal allergy time study drug dose ) . Positive urine drug screen within 28 day prior first dose study drug . Use prohibit prescription drug , grapefruit juice within 7 day first dose study drug ; prohibit medication define nonsteroidal steroidal antiinflammatory drug , analgesic include opioids ( except low dose aspirin myocardial infarction prophylaxis ) , P450 CYP3A substrates inhibitor ( strong moderate ) . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>